Therapy Areas: Diabetes
AstraZeneca reveals results from EXSCEL trial of diabetes drug Byduron
18 September 2017 -

United Kingdom-based AstraZeneca has revealed complete results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that indicated cardiovascular safety for Bydureon (exenatide extended-release) in for patients with type-2 diabetes at a wide range of CV risk, it was reported on Friday.

The product prescribed once-weekly did not increase the incidence of major adverse cardiovascular events, a composite endpoint of CV death, non-fatal heart attack (myocardial infarction) or non-fatal stroke, compared to placebo (Hazard Ratio [HR]: 0.91; 95% Confidence Interval [CI]: 0.83-1.00; p

Login
Username:

Password: